RAS-driven oncogenesis is supported by downstream antioxidant programs

Jonathan K M Lim; Gabriel Leprivier; Poul H Sorensen

doi:10.1080/23723556.2019.1654814

RAS-driven oncogenesis is supported by downstream antioxidant programs

Mol Cell Oncol. 2019 Nov 10;7(1):1654814. doi: 10.1080/23723556.2019.1654814. eCollection 2020.

Authors

Jonathan K M Lim¹, Gabriel Leprivier¹, Poul H Sorensen^{2

3}

Affiliations

¹ Department of Neuropathology, Heinrich Heine University, Düsseldorf, Germany.
² Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
³ Department of Molecular Oncology, BC Cancer, Vancouver, Canada.

Abstract

In our recent study, we demonstrated that oncogenic RAS (rat sarcoma)-mediated transformation and tumorigenesis are supported by transcriptional induction of a crucial antioxidant component, SLC7A11 (solute carrier family 7 member 11), otherwise known as XCT, a gene encoding the cystine/glutamate transporter. Our data highlight that this promotes the biosynthesis of glutathione, in turn allowing RAS transformed cells to mitigate tumorigenesis-linked oxidative stress.